Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John Bradley Schmieder sold 477 shares of the stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $285.23, for a total value of $136,054.71. Following the sale, the director now directly owns 73,467 shares in the company, valued at approximately $20,954,992.41. The sale was disclosed in a document filed with the SEC, which is available at this link.

Mesa Laboratories stock opened at $295.19 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 13.74 and a current ratio of 14.34. The stock has a market cap of $1.51 billion, a PE ratio of -421.70 and a beta of 0.41. The stock has a 50-day moving average of $280.74 and a two-hundred day moving average of $257.31. Mesa Laboratories, Inc. has a one year low of $181.90 and a one year high of $300.00.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.67. The firm had revenue of $31.86 million during the quarter, compared to analyst estimates of $30.27 million. Mesa Laboratories had a negative net margin of 2.04% and a positive return on equity of 6.39%. As a group, sell-side analysts predict that Mesa Laboratories, Inc. will post 5.84 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, March 15th. Shareholders of record on Friday, February 26th will be paid a dividend of $0.16 per share. The ex-dividend date is Thursday, February 25th. This represents a $0.64 dividend on an annualized basis and a yield of 0.22%. Mesa Laboratories’s payout ratio is 15.20%.

A number of equities research analysts recently weighed in on the company. BidaskClub cut Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 5th. KeyCorp began coverage on shares of Mesa Laboratories in a report on Monday, November 9th. They issued a “sector weight” rating and a $287.00 target price for the company. Zacks Investment Research cut shares of Mesa Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday. JPMorgan Chase & Co. assumed coverage on shares of Mesa Laboratories in a research note on Friday, October 2nd. They set a “neutral” rating and a $260.00 price objective for the company. Finally, ValuEngine downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, December 1st. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $293.33.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Mesa Laboratories by 16.3% during the third quarter. BlackRock Inc. now owns 749,976 shares of the medical instruments supplier’s stock valued at $191,065,000 after buying an additional 104,997 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in Mesa Laboratories by 4.4% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 499,349 shares of the medical instruments supplier’s stock valued at $127,214,000 after purchasing an additional 20,950 shares during the last quarter. Royce & Associates LP increased its holdings in shares of Mesa Laboratories by 1.4% in the third quarter. Royce & Associates LP now owns 310,454 shares of the medical instruments supplier’s stock valued at $79,091,000 after purchasing an additional 4,174 shares during the period. Vanguard Group Inc. increased its holdings in shares of Mesa Laboratories by 4.4% in the second quarter. Vanguard Group Inc. now owns 293,614 shares of the medical instruments supplier’s stock valued at $63,655,000 after purchasing an additional 12,383 shares during the period. Finally, State Street Corp raised its stake in shares of Mesa Laboratories by 8.4% in the third quarter. State Street Corp now owns 172,397 shares of the medical instruments supplier’s stock worth $43,920,000 after purchasing an additional 13,339 shares during the last quarter. Institutional investors and hedge funds own 88.70% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company's Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services.

See Also: Circuit Breakers

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.